Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials

  1. Garcia-Cremades, Maria 1
  2. Vučićević, Katarina 14
  3. Hendrix, Craig W 5
  4. Jayachandran, Priya 1
  5. Jarlsberg, Leah 1
  6. Grant, Robert 11
  7. Celum, Connie L 2
  8. Martin, Michael 67
  9. Baeten, Jared M 2
  10. Marrazzo, Jeanne 8
  11. Anderson, Peter 10
  12. Choopanya, Kachit 9
  13. Vanichseni, Suphak 9
  14. Glidden, David V 3
  15. Savic, Radojka M 1
  1. 1 Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA
  2. 2 Departments of Global Health, Medicine, and Epidemiology, University of Washington , Seattle, Washington , USA
  3. 3 Department of Epidemiology and Biostatistics, University of California San Francisco , San Francisco, California , USA
  4. 4 Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade-Faculty of Pharmacy , Belgrade , Serbia
  5. 5 Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University , Baltimore, Maryland , USA
  6. 6 Centers for Disease Control and Prevention, National Center For HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention , Atlanta, Georgia , USA
  7. 7 Thailand Ministry of Public Health-US CDC Collaboration , Nonthaburi , Thailand
  8. 8 Division of Infectious Diseases, University of Alabama at Birmingham Medical Center , Birmingham, Alabama , USA
  9. 9 Bangkok Tenofovir Study Group , Bangkok , Thailand
  10. 10 Department of Pharmaceutical Sciences, University of Colorado , Denver, Colorado , USA
  11. 11 Department of Medicine, University of California San Francisco , San Francisco, California , USA
Mostrar afiliaciones +
Revista:
Clinical Infectious Diseases

ISSN: 1058-4838,  1537-6591

Año de publicación: 2022

Volumen: 75

Número: 11

Páginas: 1873-1882

Tipo: Artículo

DOI: 10.1093/CID/CIAC313 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Clinical Infectious Diseases

€ Ver financiación

Información de financiación

Financiadores

Referencias bibliográficas

  • WHO, HIV/AIDS fact sheet
  • Grant, (2010), N Engl J Med, 363, pp. 2587
  • Marrazzo, (2015), N Engl J Med, 372, pp. 509
  • Baeten, (2012), N Engl J Med, 367, pp. 399
  • Thigpen, (2012), N Engl J Med, 367, pp. 423
  • Choopanya, (2013), Lancet, 381, pp. 2083
  • Karim, (2010), Science, 329, pp. 1168
  • Van Damme, (2012), N Engl J Med, 367, pp. 411
  • Amico, (2014), Clin Infect Dis, 9, pp. S55
  • Liu, (2014), AIDS Patient Care STDS, 28, pp. 622
  • Lindsey, (2009), AIDS Patient Care STDS, 23, pp. 799
  • Rudy, (2010), AIDS Patient Care STDS, 24, pp. 97
  • Murphy, (2005), Arch Pediatr Adolesc Med, 159, pp. 764
  • Hosek, (2013), J Acquir Immune Defic Syndr, 62, pp. 447
  • Molina, (2015), N Engl J Med, 373, pp. 2237
  • Bauer, (2017), NONMEM users guide: introduction to NONMEM 7.4.1, pp. 128
  • Ahn, (2008), J Pharmacokinet Pharmacodyn, 35, pp. 401
  • Lu, (2001), J Pharmacokinet Pharmacodyn, 28, pp. 343
  • Collett, (1952)
  • Holford, (2013), CPT Pharmacometrics Syst Pharmacol, 2, pp. e43
  • Donnell, (2014), J Acquir Immune Defic Syndr, 66, pp. 340
  • Kiley, (2017), N Engl J Med, 377, pp. 1990
  • García-Lerma, (2008), PLoS Med, 5, pp. e28
  • Patterson, (2011), Sci Transl Med, 3, pp. 112re4
  • Hendrix, (2013), Cell, 155, pp. 515
  • Celum, (2019), J Int AIDS Soc, 22, pp. e25298
  • Klatt, (2017), Science, 356, pp. 938
  • Spreen, (2014), J Acquir Immune Defic Syndr, 67, pp. 481
  • Cottrell, (2017), J Antimicrob Chemother, 72, pp. 1731
  • Mayer, (2020), Lancet, 396, pp. 239